Sanofi (SNY) Cash from Investing Activities (2009 - 2026)
Sanofi's (SNY) quarterly Cash from Investing Activities came in at -$2.7 billion in Q1 2026, down 226.73% year-on-year from $2.1 billion in Q1 2025, and up 6.37% quarter-over-quarter from -$2.8 billion in Q4 2025.
Sanofi (SNY) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Sanofi has disclosed Cash from Investing Activities across 8 years of filings, most recently posting -$2.7 billion for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$2.7 billion, down 226.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 152.93% YoY), and the FY2025 annual result was -$2.8 billion, up 39.52% from the prior year.
- Cash from Investing Activities came in at -$2.7 billion for Q1 2026 at Sanofi, up from -$2.8 billion in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $10.8 billion in Q2 2025 to a low of -$4.7 billion in Q4 2024.
- The 3-year median for Cash from Investing Activities is -$1.7 billion (2025), against an average of -$541.5 million.
- Across the five-year window, Cash from Investing Activities jumped 428.48% in 2025 and sank 226.73% in 2026, its largest moves.
- Sanofi's Cash from Investing Activities stood at -$4.7 billion in 2024, then surged by 39.52% to -$2.8 billion in 2025, then increased by 6.37% to -$2.7 billion in 2026.
- The last three Cash from Investing Activities figures came in at -$2.7 billion (Q1 2026), -$2.8 billion (Q4 2025), and -$369.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -1.98 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -3.92 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -1.04 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -574.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -131.00 Mn |
| 10 | Sanofi | 63.47 Mn | -6.87 Bn | 9.49 Bn | -2.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.67 Bn |
| Mar 31, 2026 | -2.67 Bn |
| Dec 31, 2025 | -2.85 Bn |
| Dec 31, 2025 | -2.85 Bn |
| Sep 30, 2025 | -369.42 Mn |
| Sep 30, 2025 | -369.42 Mn |
| Jun 30, 2025 | 10.76 Bn |
| Jun 30, 2025 | 10.76 Bn |
| Mar 31, 2025 | -816.26 Mn |
| Mar 31, 2025 | -816.26 Mn |
| Dec 31, 2024 | -4.71 Bn |
| Dec 31, 2024 | -4.71 Bn |
| Jun 30, 2024 | -3.27 Bn |
| Jun 30, 2024 | -3.27 Bn |
| Mar 31, 2024 | -404.13 Mn |
| Mar 31, 2024 | -404.13 Mn |
| Dec 31, 2021 | -100.56 Mn |
| Dec 31, 2021 | -100.56 Mn |
| Dec 31, 2020 | -105.28 Mn |
| Dec 31, 2020 | -105.28 Mn |